Industrial production has begun of Cuba’s candidate vaccines Soberana 02 and Abdala (CIGB-66), two of the four developed on the island to combat COVID-19, with progress advancing at BioCubaFarma facilities.
(...)
Cuban television reported that, during in a meeting with the President of the Republic, Dr. Vicente Vérez Bencomo, director of the Finlay Vaccine Institute, stated, "We are scaling up the process of conjugation of Soberana 02, and have been able to produce a batch of 150,000 doses that came out very well, an important scientific-technical milestone."
(..)
Cuba has extensive experience in the development and production of vaccines. At present, the national biopharmaceutical industry manufactures eight of the 11 vaccines used in the national expanded immunization program, which ensures a vaccination level in the country close to 100%, with a significant impact on the elimination of several infectious diseases and the reduction of the incidence rate of others.
Cuba scales up industrial production of candidate vaccines (Granma.cu, Feb. 18, 2021)